- Home
- FNWB vs AGEN Comparison
FNWB vs AGEN Comparison
Compare FNWB & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNWB
- AGEN
- Stock Information
- Founded
- FNWB 1923
- AGEN 1994
- Country
- FNWB United States
- AGEN United States
- Employees
- FNWB N/A
- AGEN N/A
- Industry
- FNWB Banks
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FNWB Finance
- AGEN Health Care
- Exchange
- FNWB Nasdaq
- AGEN Nasdaq
- Market Cap
- FNWB 95.2M
- AGEN 96.2M
- IPO Year
- FNWB 2015
- AGEN 2000
- Fundamental
- Price
- FNWB $10.76
- AGEN $3.32
- Analyst Decision
- FNWB Hold
- AGEN Buy
- Analyst Count
- FNWB 1
- AGEN 3
- Target Price
- FNWB $12.00
- AGEN $10.50
- AVG Volume (30 Days)
- FNWB 31.6K
- AGEN 360.9K
- Earning Date
- FNWB 01-29-2025
- AGEN 03-13-2025
- Dividend Yield
- FNWB 2.60%
- AGEN N/A
- EPS Growth
- FNWB N/A
- AGEN N/A
- EPS
- FNWB N/A
- AGEN N/A
- Revenue
- FNWB $50,900,000.00
- AGEN $160,427,000.00
- Revenue This Year
- FNWB N/A
- AGEN N/A
- Revenue Next Year
- FNWB $11.60
- AGEN $26.02
- P/E Ratio
- FNWB N/A
- AGEN N/A
- Revenue Growth
- FNWB N/A
- AGEN 59.00
- 52 Week Low
- FNWB $8.91
- AGEN $2.50
- 52 Week High
- FNWB $16.00
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- FNWB 46.62
- AGEN 45.96
- Support Level
- FNWB $10.80
- AGEN $3.09
- Resistance Level
- FNWB $12.10
- AGEN $3.68
- Average True Range (ATR)
- FNWB 0.33
- AGEN 0.25
- MACD
- FNWB -0.03
- AGEN -0.03
- Stochastic Oscillator
- FNWB 7.59
- AGEN 23.00
About FNWB First Northwest Bancorp
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).